Hypericum perforatum (St. John's wort)

What is Hypericum perforatum?

Hypericum perforatum is commonly known as St John’s wort and often used for the relief of mild anxiety, mild to moderate depression, & symptoms of stress.  St. John's wort is a shrubby plant with clusters of yellow flowers that have oval, elongated petals. Scientists believe it is native to Europe, parts of Asia and Africa, and the western United States. Both the flowers and leaves are used as medicine.

The history of Hypericum perforatum use

St John's wort has been used since the middle ages to help manage symptoms of mild anxiety and stress. It was the ancient Greek herbalists, such as Hippocrates, who originally documented the medicinal uses of St John’s wort. It was used by Roman military doctors and in the middle ages was a common ingredient in herbal ‘potions’. It is believed it is called St John’s wort because it flowers around St John’s Day (June 24th) in the Northern hemisphere.

The specific extract used by Flordis

The Flordis extract of St John’s wort is known as Ze 117 and has been shown to assist in the relief of nervous tension, stress and mild anxiety in a number of clinical trials. Ze 117 is the result of a patented production process, helping to ensure a reliable, high quality product.

Natural medicines can vary considerably depending on how they are produced. Flordis believes it’s the science behind growing, harvesting and processing that delivers the true health benefits of natural medicine. That’s why in the making of a Flordis medicine, careful attention is applied to plant species and growing methods through to cultivation and harvest, using precise processes to help produce consistent crops. This is continued with extracting and manufacturing of specific ingredients following a series of strict controls to help deliver a consistent medicine from one batch to the next. 

It is this specific medicine that is tested in clinical trials and it’s the same medicine that you receive, which is one of the reasons you can feel confident about its effectiveness. Flordis medicines follow processes where all of the steps involved in the growth and manufacture of the natural medicine are tightly controlled to reduce variability and to help ensure consistency.

The specific extract of St John’s wort used in the Flordis extract, Ze 117 contains consistently low levels (<1%) of the constituent hyperforin,1 which is considered to be possibly responsible for the interaction between some St John’s wort products and certain medications.

Scientific studies suggest that Ze 117 inhibits the re-uptake of noradrenaline, serotonin and dopamine. These neurotransmitters have a range of effects in the body.

How it works

The whole plant extract is considered to be responsible for the therapeutic actions of St John’s wort. 

St John’s wort works in several ways to  relieve the symptoms of mild anxiety and stress.2,3

St John’s wort contains many chemical compounds, some of which are believed to help by preventing nerve cells in the brain from reabsorbing the chemical messenger serotonin, or by reducing levels of a protein involved in the body’s immune system functioning.  

Scientific studies suggest that Ze 117 inhibits the re-uptake of noradrenaline, serotonin and dopamine. These neurotransmitters have a range of effects in the body.

Neurotransmitters that are likely to be affected by Ze 117

Key studies on Ze 117

Ze 117 has been studied in over 2000 people, including a one year study that showed that it was well tolerated as well as continued improvement of symptoms during this time. 4

Ze 117 has been shown to significantly improve symptoms associated with anxiety, mild to moderate depression, and stress4,5,6,7 with good tolerability. 4,5

More from Flordis

Remotiv

For the relief of symptoms of anxiety, mild to moderate depression & stress
Learn more

KeenMind

Supports memory retention, cognitive function and calm focus
Learn more

You might like

References

1. Wurglics, M. et al. (2001) Journal Am Pharm Assoc, 41(4):560-566. 2. Holsboer-Trachsler and Vanoni. (2007) Auflage, 88-89. 3. Rang, H.P. et al. (1995) Pharmacology, 3rd Edition, 492-502. 4. Woelk, H. et al. (2000) BMJ, 21:536-9. 5. Schrader, E. (2000) Int Clin Psychopharma, 16:277-283. 6. Schrader, E. et al. (1998) Human Psychopharmacology, 13:163-169. 7. Brattström, A. (2009) Journal Phymed, 16:277-283.